In This Story
Avantor Inc. (AVTR-0.91%) has submitted its Form 10-K filing for the fiscal year ended December 31, 2024.
The filing reports net sales of $6,783.6 million, a decrease from $6,967.2 million in the previous year. The decline is attributed to reduced customer demand in both the Laboratory Solutions and Bioscience Production segments.
Operating income for the year was $1,084.8 million, up from $696.4 million in 2023. This increase was primarily driven by a gain on the sale of the Clinical Services business.
Net income for the year was $711.5 million, an increase from $321.1 million in 2023. This improvement was due to higher operating income and lower interest expenses.
Avantor's 2024 restructuring program, part of a cost transformation initiative, incurred $82.8 million in charges aimed at improving cost efficiency.
The company reported a decrease in gross margin to 33.6% from 33.9% in 2023, affected by inflationary pressures.
Cash provided by operating activities was $840.8 million, slightly down from $870.0 million in 2023, influenced by higher cash costs related to the cost transformation initiative.
Avantor completed the sale of its Clinical Services business for approximately $595.0 million, resulting in a gain of $446.6 million.
The company made significant debt repayments in 2024, including $690.0 million on U.S. dollar term loans and $526.4 million on Euro term loans.
Avantor continues to focus on its cost transformation initiative, aiming for $300 million in annual gross run-rate savings by the end of 2026.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Avantor Inc. annual 10-K report dated February 7, 2025. To report an error, please email earnings@qz.com.